Pharsight

1. Allegra patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5578610	CHATTEM SANOFI	Piperidine derivatives	Nov, 2013 (10 years ago)
US7138524	CHATTEM SANOFI	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof	May, 2014 (9 years ago)
US7135571	CHATTEM SANOFI	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof	May, 2014 (9 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6399632 (Pediatric)	CHATTEM SANOFI	Method of providing an antihistaminic effect in a hepatically impaired patient	Nov, 2012 (11 years ago)
US6187791 (Pediatric)	CHATTEM SANOFI	Method of providing an antihistaminic effect in a hepatically impaired patient	Nov, 2012 (11 years ago)
US5578610	CHATTEM SANOFI	Piperidine derivatives	Nov, 2013 (10 years ago)
US5578610 (Pediatric)	CHATTEM SANOFI	Piperidine derivatives	May, 2014 (9 years ago)
US7135571 (Pediatric)	CHATTEM SANOFI	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof	Nov, 2014 (9 years ago)
US7138524 (Pediatric)	CHATTEM SANOFI	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof	Nov, 2014 (9 years ago)
US5932247	CHATTEM SANOFI	Pharmaceutical composition for piperidinoalkanol compounds	Feb, 2015 (9 years ago)
US6113942	CHATTEM SANOFI	Pharmaceutical composition for piperidinoalkanol compounds	Feb, 2015 (9 years ago)
US5855912	CHATTEM SANOFI	Pharmaceutical compositions for piperidinalkanol compounds	Feb, 2015 (9 years ago)
US5738872	CHATTEM SANOFI	Pharmaceutical composition for piperidinoalkanol compounds	Feb, 2015 (9 years ago)
US5738872 (Pediatric)	CHATTEM SANOFI	Pharmaceutical composition for piperidinoalkanol compounds	Aug, 2015 (8 years ago)
US6113942 (Pediatric)	CHATTEM SANOFI	Pharmaceutical composition for piperidinoalkanol compounds	Aug, 2015 (8 years ago)
US5932247 (Pediatric)	CHATTEM SANOFI	Pharmaceutical composition for piperidinoalkanol compounds	Aug, 2015 (8 years ago)
US5855912 (Pediatric)	CHATTEM SANOFI	Pharmaceutical compositions for piperidinalkanol compounds	Aug, 2015 (8 years ago)
US6037353	CHATTEM SANOFI	Method of providing an antihistaminic effect in a hepatically impaired patient	Mar, 2017 (7 years ago)
US6037353 (Pediatric)	CHATTEM SANOFI	Method of providing an antihistaminic effect in a hepatically impaired patient	Sep, 2017 (6 years ago)

Drugs and Companies using FEXOFENADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 25 July, 1996

Treatment: Use in treating allergic reactions; Treatment of allergic rhinitis; Relief of symptoms associated with seasonal allergic rhinitis in children 2 to 11 years and for the relief of symptoms associated wi...

Dosage: CAPSULE;ORAL; SUSPENSION;ORAL

Strength	Dosage	Availability
60MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE;ORAL	Discontinued
30MG/5ML	SUSPENSION;ORAL	Discontinued

ALLEGRA family patents

2. Allegra Allergy patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5578610	CHATTEM SANOFI	Piperidine derivatives	Nov, 2013 (10 years ago)
US7135571	CHATTEM SANOFI	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof	May, 2014 (9 years ago)
US7138524	CHATTEM SANOFI	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof	May, 2014 (9 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6399632 (Pediatric)	CHATTEM SANOFI	Method of providing an antihistaminic effect in a hepatically impaired patient	Nov, 2012 (11 years ago)
US6187791 (Pediatric)	CHATTEM SANOFI	Method of providing an antihistaminic effect in a hepatically impaired patient	Nov, 2012 (11 years ago)
US5578610 (Pediatric)	CHATTEM SANOFI	Piperidine derivatives	May, 2014 (9 years ago)
US7138524 (Pediatric)	CHATTEM SANOFI	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof	Nov, 2014 (9 years ago)
US7135571 (Pediatric)	CHATTEM SANOFI	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof	Nov, 2014 (9 years ago)
US5932247	CHATTEM SANOFI	Pharmaceutical composition for piperidinoalkanol compounds	Feb, 2015 (9 years ago)
US6113942	CHATTEM SANOFI	Pharmaceutical composition for piperidinoalkanol compounds	Feb, 2015 (9 years ago)
US5855912	CHATTEM SANOFI	Pharmaceutical compositions for piperidinalkanol compounds	Feb, 2015 (9 years ago)
US5932247 (Pediatric)	CHATTEM SANOFI	Pharmaceutical composition for piperidinoalkanol compounds	Aug, 2015 (8 years ago)
US5855912 (Pediatric)	CHATTEM SANOFI	Pharmaceutical compositions for piperidinalkanol compounds	Aug, 2015 (8 years ago)
US6113942 (Pediatric)	CHATTEM SANOFI	Pharmaceutical composition for piperidinoalkanol compounds	Aug, 2015 (8 years ago)
US6037353	CHATTEM SANOFI	Method of providing an antihistaminic effect in a hepatically impaired patient	Mar, 2017 (7 years ago)
US6037353 (Pediatric)	CHATTEM SANOFI	Method of providing an antihistaminic effect in a hepatically impaired patient	Sep, 2017 (6 years ago)

Drugs and Companies using FEXOFENADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 January, 2011

Treatment: Relief of symptoms associated with respiratory allergies and for the relief of symptoms associated with hives (urticaria) in adults and children 6 years of age and older and 12 years of age and older

Dosage: TABLET;ORAL

Strength	Dosage	Availability
180MG	TABLET;ORAL	Over the counter
60MG	TABLET;ORAL	Over the counter

ALLEGRA ALLERGY family patents

3. Allegra Hives patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5578610	CHATTEM SANOFI	Piperidine derivatives	Nov, 2013 (10 years ago)
US7135571	CHATTEM SANOFI	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof	May, 2014 (9 years ago)
US7138524	CHATTEM SANOFI	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof	May, 2014 (9 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6399632 (Pediatric)	CHATTEM SANOFI	Method of providing an antihistaminic effect in a hepatically impaired patient	Nov, 2012 (11 years ago)
US6187791 (Pediatric)	CHATTEM SANOFI	Method of providing an antihistaminic effect in a hepatically impaired patient	Nov, 2012 (11 years ago)
US5578610 (Pediatric)	CHATTEM SANOFI	Piperidine derivatives	May, 2014 (9 years ago)
US7135571 (Pediatric)	CHATTEM SANOFI	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof	Nov, 2014 (9 years ago)
US7138524 (Pediatric)	CHATTEM SANOFI	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof	Nov, 2014 (9 years ago)
US5855912	CHATTEM SANOFI	Pharmaceutical compositions for piperidinalkanol compounds	Feb, 2015 (9 years ago)
US6113942	CHATTEM SANOFI	Pharmaceutical composition for piperidinoalkanol compounds	Feb, 2015 (9 years ago)
US5932247	CHATTEM SANOFI	Pharmaceutical composition for piperidinoalkanol compounds	Feb, 2015 (9 years ago)
US5932247 (Pediatric)	CHATTEM SANOFI	Pharmaceutical composition for piperidinoalkanol compounds	Aug, 2015 (8 years ago)
US5855912 (Pediatric)	CHATTEM SANOFI	Pharmaceutical compositions for piperidinalkanol compounds	Aug, 2015 (8 years ago)
US6113942 (Pediatric)	CHATTEM SANOFI	Pharmaceutical composition for piperidinoalkanol compounds	Aug, 2015 (8 years ago)
US6037353	CHATTEM SANOFI	Method of providing an antihistaminic effect in a hepatically impaired patient	Mar, 2017 (7 years ago)
US6037353 (Pediatric)	CHATTEM SANOFI	Method of providing an antihistaminic effect in a hepatically impaired patient	Sep, 2017 (6 years ago)

Drugs and Companies using FEXOFENADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 January, 2011

Dosage: TABLET;ORAL

Strength	Dosage	Availability
180MG	TABLET;ORAL	Over the counter
60MG	TABLET;ORAL	Discontinued

ALLEGRA HIVES family patents

4. Allegra-d 12 Hour Allergy And Congestion patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5578610	CHATTEM SANOFI	Piperidine derivatives	Nov, 2013 (10 years ago)
US7135571	CHATTEM SANOFI	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof	May, 2014 (9 years ago)
US7138524	CHATTEM SANOFI	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof	May, 2014 (9 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6399632 (Pediatric)	CHATTEM SANOFI	Method of providing an antihistaminic effect in a hepatically impaired patient	Nov, 2012 (11 years ago)
US6187791 (Pediatric)	CHATTEM SANOFI	Method of providing an antihistaminic effect in a hepatically impaired patient	Nov, 2012 (11 years ago)
US5578610 (Pediatric)	CHATTEM SANOFI	Piperidine derivatives	May, 2014 (9 years ago)
US7135571 (Pediatric)	CHATTEM SANOFI	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof	Nov, 2014 (9 years ago)
US7138524 (Pediatric)	CHATTEM SANOFI	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof	Nov, 2014 (9 years ago)
US6113942	CHATTEM SANOFI	Pharmaceutical composition for piperidinoalkanol compounds	Feb, 2015 (9 years ago)
US5855912	CHATTEM SANOFI	Pharmaceutical compositions for piperidinalkanol compounds	Feb, 2015 (9 years ago)
US5855912 (Pediatric)	CHATTEM SANOFI	Pharmaceutical compositions for piperidinalkanol compounds	Aug, 2015 (8 years ago)
US6113942 (Pediatric)	CHATTEM SANOFI	Pharmaceutical composition for piperidinoalkanol compounds	Aug, 2015 (8 years ago)
US6037353	CHATTEM SANOFI	Method of providing an antihistaminic effect in a hepatically impaired patient	Mar, 2017 (7 years ago)
US6037353 (Pediatric)	CHATTEM SANOFI	Method of providing an antihistaminic effect in a hepatically impaired patient	Sep, 2017 (6 years ago)
US6039974	CHATTEM SANOFI	Pharmaceutical composition for combination of piperidinoalkanol-decongestant	Jul, 2018 (5 years ago)

Drugs and Companies using FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 January, 2011

Treatment: Relief of symptoms associated with respiratory allergies, swelling of the nasal passages and sinus congestion and pressure in adults and children 12 years of age and older

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
60MG;120MG	TABLET, EXTENDED RELEASE;ORAL	Over the counter

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION family patents

5. Allegra-d 24 Hour Allergy And Congestion patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5578610	CHATTEM SANOFI	Piperidine derivatives	Nov, 2013 (10 years ago)
US7138524	CHATTEM SANOFI	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof	May, 2014 (9 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6187791 (Pediatric)	CHATTEM SANOFI	Method of providing an antihistaminic effect in a hepatically impaired patient	Nov, 2012 (11 years ago)
US6399632 (Pediatric)	CHATTEM SANOFI	Method of providing an antihistaminic effect in a hepatically impaired patient	Nov, 2012 (11 years ago)
US5578610 (Pediatric)	CHATTEM SANOFI	Piperidine derivatives	May, 2014 (9 years ago)
US7138524 (Pediatric)	CHATTEM SANOFI	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof	Nov, 2014 (9 years ago)
US6037353	CHATTEM SANOFI	Method of providing an antihistaminic effect in a hepatically impaired patient	Mar, 2017 (7 years ago)
US6037353 (Pediatric)	CHATTEM SANOFI	Method of providing an antihistaminic effect in a hepatically impaired patient	Sep, 2017 (6 years ago)
USRE39069	CHATTEM SANOFI	Multi-layered osmotic device	May, 2018 (5 years ago)
US6613357	CHATTEM SANOFI	Osmotic device containing pseudoephedrine and an H1 antagonist	Dec, 2020 (3 years ago)

Drugs and Companies using FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 January, 2011

Treatment: Relief of symptoms associated with respiratory allergies, swelling of the nasal passages and sinus congestion and pressure in adults and children 12 years of age and older

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
180 mg/240 mg	06 Jun, 2007	1	22 Jun, 2011	25 Dec, 2020	Eligible

Strength	Dosage	Availability
180MG;240MG	TABLET, EXTENDED RELEASE;ORAL	Over the counter

ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION family patents

6. Children's Allegra Allergy patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5578610	CHATTEM SANOFI	Piperidine derivatives	Nov, 2013 (10 years ago)
US7138524	CHATTEM SANOFI	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof	May, 2014 (9 years ago)
US7135571	CHATTEM SANOFI	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof	May, 2014 (9 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6399632 (Pediatric)	CHATTEM SANOFI	Method of providing an antihistaminic effect in a hepatically impaired patient	Nov, 2012 (11 years ago)
US6187791 (Pediatric)	CHATTEM SANOFI	Method of providing an antihistaminic effect in a hepatically impaired patient	Nov, 2012 (11 years ago)
US5578610 (Pediatric)	CHATTEM SANOFI	Piperidine derivatives	May, 2014 (9 years ago)
US7135571 (Pediatric)	CHATTEM SANOFI	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof	Nov, 2014 (9 years ago)
US7138524 (Pediatric)	CHATTEM SANOFI	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof	Nov, 2014 (9 years ago)
US5738872	CHATTEM SANOFI	Pharmaceutical composition for piperidinoalkanol compounds	Feb, 2015 (9 years ago)
US6113942	CHATTEM SANOFI	Pharmaceutical composition for piperidinoalkanol compounds	Feb, 2015 (9 years ago)
US5855912	CHATTEM SANOFI	Pharmaceutical compositions for piperidinalkanol compounds	Feb, 2015 (9 years ago)
US5932247	CHATTEM SANOFI	Pharmaceutical composition for piperidinoalkanol compounds	Feb, 2015 (9 years ago)
US5932247 (Pediatric)	CHATTEM SANOFI	Pharmaceutical composition for piperidinoalkanol compounds	Aug, 2015 (8 years ago)
US6113942 (Pediatric)	CHATTEM SANOFI	Pharmaceutical composition for piperidinoalkanol compounds	Aug, 2015 (8 years ago)
US5855912 (Pediatric)	CHATTEM SANOFI	Pharmaceutical compositions for piperidinalkanol compounds	Aug, 2015 (8 years ago)
US6037353	CHATTEM SANOFI	Method of providing an antihistaminic effect in a hepatically impaired patient	Mar, 2017 (7 years ago)
US6037353 (Pediatric)	CHATTEM SANOFI	Method of providing an antihistaminic effect in a hepatically impaired patient	Sep, 2017 (6 years ago)
US6723348	CHATTEM SANOFI	Orodispersible tablets containing fexofenadine	Nov, 2021 (2 years ago)
US8933097	CHATTEM SANOFI	Fexofenadine suspension formulation	Aug, 2030 (6 years from now)

Drugs and Companies using FEXOFENADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 January, 2011

Dosage: SUSPENSION;ORAL; TABLET;ORAL; TABLET, ORALLY DISINTEGRATING;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
30 mg/5 mL	25 Jan, 2010	1	18 Nov, 2014	14 Mar, 2017	Eligible
30 mg, 60 mg and 180 mg

Strength	Dosage	Availability
30MG/5ML	SUSPENSION;ORAL	Over the counter
30MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET;ORAL	Discontinued
30MG	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued

CHILDREN'S ALLEGRA ALLERGY family patents

7. Children's Allegra Hives patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5578610	CHATTEM SANOFI	Piperidine derivatives	Nov, 2013 (10 years ago)
US7135571	CHATTEM SANOFI	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof	May, 2014 (9 years ago)
US7138524	CHATTEM SANOFI	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof	May, 2014 (9 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6399632 (Pediatric)	CHATTEM SANOFI	Method of providing an antihistaminic effect in a hepatically impaired patient	Nov, 2012 (11 years ago)
US6187791 (Pediatric)	CHATTEM SANOFI	Method of providing an antihistaminic effect in a hepatically impaired patient	Nov, 2012 (11 years ago)
US5578610 (Pediatric)	CHATTEM SANOFI	Piperidine derivatives	May, 2014 (9 years ago)
US7138524 (Pediatric)	CHATTEM SANOFI	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof	Nov, 2014 (9 years ago)
US7135571 (Pediatric)	CHATTEM SANOFI	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof	Nov, 2014 (9 years ago)
US6113942	CHATTEM SANOFI	Pharmaceutical composition for piperidinoalkanol compounds	Feb, 2015 (9 years ago)
US5738872	CHATTEM SANOFI	Pharmaceutical composition for piperidinoalkanol compounds	Feb, 2015 (9 years ago)
US5855912	CHATTEM SANOFI	Pharmaceutical compositions for piperidinalkanol compounds	Feb, 2015 (9 years ago)
US5932247	CHATTEM SANOFI	Pharmaceutical composition for piperidinoalkanol compounds	Feb, 2015 (9 years ago)
US5932247 (Pediatric)	CHATTEM SANOFI	Pharmaceutical composition for piperidinoalkanol compounds	Aug, 2015 (8 years ago)
US5855912 (Pediatric)	CHATTEM SANOFI	Pharmaceutical compositions for piperidinalkanol compounds	Aug, 2015 (8 years ago)
US6113942 (Pediatric)	CHATTEM SANOFI	Pharmaceutical composition for piperidinoalkanol compounds	Aug, 2015 (8 years ago)
US6037353	CHATTEM SANOFI	Method of providing an antihistaminic effect in a hepatically impaired patient	Mar, 2017 (7 years ago)
US6037353 (Pediatric)	CHATTEM SANOFI	Method of providing an antihistaminic effect in a hepatically impaired patient	Sep, 2017 (6 years ago)
US6723348	CHATTEM SANOFI	Orodispersible tablets containing fexofenadine	Nov, 2021 (2 years ago)
US8933097	CHATTEM SANOFI	Fexofenadine suspension formulation	Aug, 2030 (6 years from now)

Drugs and Companies using FEXOFENADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 January, 2011

Treatment: Relief of symptoms associated with respiratory allergies in adults and children 2 years of age and older and for the relief of symptoms associated with hives (urticaria) in adults and children 6 year...

Dosage: SUSPENSION;ORAL; TABLET;ORAL; TABLET, ORALLY DISINTEGRATING;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
30 mg/5 mL	25 Jan, 2010	1	18 Nov, 2014	14 Mar, 2017	Eligible
30 mg, 60 mg and 180 mg

Strength	Dosage	Availability
30MG/5ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	SUSPENSION;ORAL	Discontinued
30MG	TABLET;ORAL	Discontinued
30MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued

CHILDREN'S ALLEGRA HIVES family patents

8. Nasacort Allergy 24 Hour patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7977045	CHATTEM SANOFI	Aqueous-based pharmaceutical composition	Jul, 2016 (7 years ago)
US6143329	CHATTEM SANOFI	Aqueous-based pharmaceutical composition	Jul, 2016 (7 years ago)
US5976573	CHATTEM SANOFI	Aqueous-based pharmaceutical composition	Jul, 2016 (7 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Sep 19, 2011

Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient

Market Authorisation Date: 20 May, 1996

Treatment: NA

Dosage: SPRAY, METERED;NASAL

Strength	Dosage	Availability
0.055MG/SPRAY	SPRAY, METERED;NASAL	Over the counter

NASACORT ALLERGY 24 HOUR family patents

9. Nicoderm Cq patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5508038	CHATTEM SANOFI	Polyisobutylene adhesives for transdermal devices	Apr, 2013 (11 years ago)
US9205059	CHATTEM SANOFI	Transparent transdermal nicotine delivery devices	Dec, 2019 (4 years ago)
US8999379	CHATTEM SANOFI	Transparent transdermal nicotine delivery devices	Feb, 2020 (4 years ago)
US8663680	CHATTEM SANOFI	Transparent transdermal nicotine delivery devices	Feb, 2020 (4 years ago)
US8075911	CHATTEM SANOFI	Transparent transdermal nicotine delivery devices	May, 2021 (2 years ago)

Drugs and Companies using NICOTINE ingredient

Market Authorisation Date: 02 August, 1996

Treatment: A method to reduce withdrawal symptoms, including nicotine craving, associated with smoking cessation

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
7 mg/24 hrs 14 mg/24 hrs 21 mg/24 hrs	30 May, 2014	1		22 May, 2021	Extinguished

Strength	Dosage	Availability
14MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Over the counter
21MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Over the counter
7MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Over the counter

NICODERM CQ family patents

10. Xyzal patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5698558	CHATTEM SANOFI	Methods for treating allergic disorders using optically pure (-) cetirizine	Jul, 2013 (10 years ago)
US5698558 (Pediatric)	CHATTEM SANOFI	Methods for treating allergic disorders using optically pure (-) cetirizine	Jan, 2014 (10 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
Pediatric Exclusivity(PED)	Feb 21, 2013
New Patient Population(NPP)	Aug 21, 2012

Drugs and Companies using LEVOCETIRIZINE DIHYDROCHLORIDE ingredient

Market Authorisation Date: 28 January, 2008

Treatment: Relief of symptoms associated with seasonal and perennial allergic rhinitis

Dosage: SOLUTION;ORAL; TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.5 mg/mL	14 Jan, 2009	1	07 Nov, 2011	24 Sep, 2012	Eligible
5 mg	17 Dec, 2007	1	26 Nov, 2010	24 Sep, 2012	Eligible

Strength	Dosage	Availability
2.5MG/5ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	SOLUTION;ORAL	Discontinued
5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET;ORAL	Discontinued

XYZAL family patents

11. Xyzal Allergy 24hr patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP05758582A	2010-06-23	Zentiva k.s.	Revoked

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US8633194	December, 2018	FWD Entered	UCB Biopharma Sprl	Apotex Inc.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8633194	CHATTEM SANOFI	Pharmaceutical composition of piperazine derivatives	Oct, 2027 (3 years from now)

Drugs and Companies using LEVOCETIRIZINE DIHYDROCHLORIDE ingredient

Market Authorisation Date: 31 January, 2017

Treatment: NA

Dosage: SOLUTION;ORAL

Pharsight

Chattem Sanofi patents expiration

1. Allegra patents expiration

ALLEGRA family patents

2. Allegra Allergy patents expiration

ALLEGRA ALLERGY family patents

3. Allegra Hives patents expiration

ALLEGRA HIVES family patents

4. Allegra-d 12 Hour Allergy And Congestion patents expiration

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION family patents

5. Allegra-d 24 Hour Allergy And Congestion patents expiration

ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION family patents

6. Children's Allegra Allergy patents expiration

CHILDREN'S ALLEGRA ALLERGY family patents

7. Children's Allegra Hives patents expiration

CHILDREN'S ALLEGRA HIVES family patents

8. Nasacort Allergy 24 Hour patents expiration

NASACORT ALLERGY 24 HOUR family patents

9. Nicoderm Cq patents expiration

NICODERM CQ family patents

10. Xyzal patents expiration

XYZAL family patents

11. Xyzal Allergy 24hr patents expiration

XYZAL ALLERGY 24HR family patents

Related content